Chadwick Terence King

USPTO Granted Patents = 59 (Patent Applications = 30)

CIPO Patents = 8 (Patent Applications = 5)

EPO Patents = 23 (Patent Applications = 21)

Average Co-Inventor Count = 6.8

ph-index = 12

Forward Citations = 693(Granted Patents)

Forward Citations (Not Self Cited) = 586(Oct 12, 2025)

Inventors with similar research interests:

Location History:

North Vancouver, CA (US) (2015 - 2017)
Vancouver, CA (2007 - 2024)

Company Filing History:

Kiniksa Pharmaceuticals, Ltd.

patents

4. 3 out of 75

Amgen Research (munich) Gmbh

6. 2 out of 832,680

Other

patents

where one patent can have more than one assignee

Years Active: 2007-2025

Loading Chart...

59 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12441796 - Antibody constructs for CDH19 and CD3 (2025-10-14),

2. 12134652 - Human CGRP receptor binding proteins (2024-11-05),

3. 12122841 - Human CGRP receptor binding proteins (2024-10-22),

4. 12122837 - Oncostatin M receptor antigen binding proteins (2024-10-22),

5. 12116413 - Human antigen binding proteins that bind β-klotho, FGF receptors and complexes thereof (2024-10-15),

6. 11965029 - ST2 antigen binding proteins (2024-04-23),

7. 11897965 - Anti-Jagged1 antigen binding proteins (2024-02-13),

8. 11897963 - Anti-Jagged1 antigen binding proteins (2024-02-13),

9. 11498964 - Antibody constructs for CDH19 and CD3 (2022-11-15),

10. 11492411 - Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof (2022-11-08),

11. 11248052 - Antigen binding proteins that bind to a complex comprising β-Klotho and an FGF receptor (2022-02-15),

12. 11059895 - ST2 antigen binding proteins (2021-07-13),

13. 11053311 - Antibodies targeting CDH19 for melanoma (2021-07-06),

14. 10570205 - Human antigen binding proteins that bind β-Klotho, FGF receptors and complexes thereof (2020-02-25),

15. 10526411 - Methods and compositions relating to anti-CCR7 antigen binding proteins (2020-01-07),

Title: The Innovative Journey of Chadwick Terence King

Introduction:

Chadwick Terence King, a visionary inventor based in North Vancouver, CA, has left a significant mark in the field of biomedical innovations. With an impressive portfolio of 51 patents to his name, King is renowned for his groundbreaking work in the development of cutting-edge medical technologies.

Latest Patents:

Among his latest patents, Chadwick Terence King has introduced revolutionary antibody constructs for CDH19 and CD3. These constructs have the potential to revolutionize the treatment of melanoma by specifically targeting cells with high precision. Additionally, his work on antibodies directed to deletion mutants of the epidermal growth factor receptor showcases his relentless pursuit of novel solutions in the healthcare domain.

Career Highlights:

Having worked at prominent companies such as Amgen Inc. and Amgen Fremont Inc., Chadwick Terence King has honed his skills and expertise in the biopharmaceutical sector. His innovative contributions have played a pivotal role in advancing the field, earning him accolades for his commitment to excellence and forward-thinking approach.

Collaborations:

Throughout his career, Chadwick Terence King has collaborated with distinguished professionals in the industry, including Ian Nevin Foltz and Randal Robert Ketchem. These collaborations have not only enriched his projects but have also fostered a culture of innovation and knowledge sharing within the organizations he has been a part of.

Conclusion:

In conclusion, Chadwick Terence King stands as a beacon of innovation, continuously pushing the boundaries of what is possible in the realm of biomedical inventions. His relentless pursuit of excellence and his unwavering commitment to creating impactful solutions make him a true trailblazer in the field. Chadwick Terence King's contributions will continue to inspire future generations of inventors and shape the landscape of medical advancements for years to come.

This text is generated by artificial intelligence and may not be accurate.